Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
Article
Nature 448, 561-566 (11 July 2007) | doi:10.1038/nature05945;
Open Innovation Challenges
-
Single-cell Analysis Platform
This Challenge is looking for novel approaches to analyzing changes at a single-cell level. This is...
-
Novel Approaches to Protecting Maize from Insect Damage
The Seeker is looking for novel approaches to protecting maize from insect damage. This Challenge re...
nature jobs
Senior Scientific Manager / Chief Scientific Manager for Metabolic Disorder and Cardiavascular Area In Vivo Pharmacology / Biology
- Syngene International
- Bangalore, Karnataka 560099 India
System Engineer (Simulation and Modelling)
- Praj Matrix - Praj Industries Ltd
- Pune, Maharashtra Pune-411021 India
Identification of the transforming EML4|[ndash]|ALK fusion gene in non-small-cell lung cancer
Improvement in the clinical outcome of lung cancer is likely to be achieved by identification of the molecular events that underlie its pathogenesis. Here we show that a small inversion within chromosome 2p results in the formation of a fusion gene comprising portions of the echinoderm microtubule-associated protein-like 4 (EML4) gene and the anaplastic lymphoma kinase (ALK) gene in non-small-cell lung cancer (NSCLC) cells. Mouse 3T3 fibroblasts forced to express this human fusion tyrosine kinase generated transformed foci in culture and subcutaneous tumours in nude mice. The EML4–ALK fusion transcript was detected in 6.7% (5 out of 75) of NSCLC patients examined; these individuals were distinct from those harbouring mutations in the epidermal growth factor receptor gene. Our data demonstrate that a subset of NSCLC patients may express a transforming fusion kinase that is a promising candidate for a therapeutic target as well as for a diagnostic molecular marker in NSCLC.
&
Abstract
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).

